Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kristin M. Wessel
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
National Institutes of Health,
United States Food and Drug Administration,
Center for Drug Evaluation and Research,
National Cancer Institute,
Center for Cancer Research
ORCID:
0009-0000-8776-1969
Observed ORCID:
0009-0000-8776-1969
OpenAlex ID:
A5090763792
Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis
2021
·
Sabina Kaczanowska
, Daniel W. Beury
, et al.
·
Cell
·
212
PDF
Adoptive Cell Therapy in Pediatric and Young Adult Solid Tumors: Current Status and Future Directions
2022
·
John A. Ligon
, Kristin M. Wessel
, et al.
·
Frontiers in Immunology
·
16
PDF
Considerations for Clinical Trial Design in Relapsed and Refractory Osteosarcoma: An FDA Symposium
2026
·
Kristin M. Wessel
, Katherine A. Janeway
, et al.
·
Clinical Cancer Research
·
7
PDF
Dosage Optimization of Pediatric Oncology Products: Our Patients Deserve Better
2025
·
Kristin M. Wessel
, Nicole Drezner
, et al.
·
Clinical Cancer Research
·
4
Show more works
View as search
Works count:
4
Citation count:
239
H-index:
4
I10-index:
2
Year
Topic
Type